LAS VEGAS, Aug. 26, 2025 /PRNewswire/ -- AcariaHealth, a leader in specialty pharmacy solutions and a Centene Corporation company (NYSE: CNC), is taking center stage at the 2025 Healthcare Advocate Summit (Sept. 2–5) in Las Vegas with a first-of-its-kind "Reimagine Access" Hackathon and two can't-miss expert sessions.Reimagine Access: A Hackathon for Healthcare AdvocatesTuesday, Sept. 2 | 1:00–3:30 PM PT | Florentine 1–11This dynamic, hands-on session brings together healthcare advocates, providers, and pha ...

Core Insights - Centene Corporation (CNC) relies on its Health Benefit Ratio (HBR) as a key profitability measure, with sensitivity to changes in Medicaid and ACA marketplace plans due to their thinner margins [1][2] Group 1: Financial Performance - Centene's HBR increased by 550 basis points in Q2 2025, driven by higher medical costs, lower Marketplace risk adjustment transfers, and a Medicare Advantage premium deficiency reserve [2][9] - The company's shares have declined by 51.5% year to date, underperforming the industry [7] Group 2: Cost Management Strategies - To address rising medical costs, Centene is enhancing utilization management, expanding value-based care contracts, tightening pharmacy cost controls, and pursuing digital efficiency investments [3][9] - Streamlining operations through divestitures is also part of Centene's strategy to maintain operational discipline [3] Group 3: Regulatory Environment - The newly enacted One Big Beautiful Bill Act introduces structural challenges, including cuts to Medicaid funding, stricter verification requirements, and ACA enrollment limits, which may reduce membership and increase administrative costs [4] Group 4: Future Outlook - Balancing medical cost containment with careful enrollment management is crucial for driving profitability, with Centene's scale and government program expertise providing resilience despite near-term margin pressures [5] - The consensus estimate for CNC's 2025 revenues indicates a year-over-year increase, while EPS estimates suggest a decline [12]

Core Viewpoint - Class action lawsuits have been filed against Hims & Hers Health, iRobot Corporation, and Centene Corporation, alleging that these companies made materially false and misleading statements regarding their business operations and prospects, which led to investor losses [2][3][4]. Group 1: Hims & Hers Health, Inc. (NYSE: HIMS) - The class period for Hims is from April 29, 2025, to June 22, 2025, with a lead plaintiff deadline of August 25, 2025 [2]. - Allegations include deceptive promotion of illegitimate versions of Wegovy, risking patient safety, and a substantial risk of termination of collaboration with Novo Nordisk [2]. - Defendants' positive statements about the company's business were materially misleading and lacked a reasonable basis [2]. Group 2: iRobot Corporation (NASDAQ: IRBT) - The class period for iRobot is from January 29, 2024, to March 11, 2025, with a lead plaintiff deadline of September 5, 2025 [3]. - Allegations state that iRobot overstated the effectiveness of its Restructuring Plan post-Amazon Acquisition termination, raising doubts about its ability to operate profitably as a standalone company [3]. - Defendants' positive statements regarding the company's prospects were materially misleading and lacked a reasonable basis [3]. Group 3: Centene Corporation (NYSE: CNC) - The class period for Centene is from December 12, 2024, to June 30, 2025, with a lead plaintiff deadline of September 8, 2025 [4]. - Allegations include failure to disclose lower-than-anticipated enrollment and increased market morbidity based on preliminary analysis of over two-thirds of Centene's marketplace share [4]. - Defendants' positive statements about the company's business operations were materially misleading and lacked a reasonable basis [4].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified class period may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3].

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Levi & Korsinsky, LLP notifies investors in Centene Corporation ("Centene" or the "Company") (NYSE: CNC) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Centene investors who were adversely affected by alleged securities fraud between December 12, 2024 and June 30, 2025. Follow the link below to get more information and be contacted by a member of our team: https://zlk.com/pslra-1/centene-corporation-lawsuit ...

Core Viewpoint - A securities class-action lawsuit has been filed against Centene Corporation, alleging that the company misrepresented its financial health and market conditions to investors [1][2]. Group 1: Lawsuit Details - The lawsuit, titled Lunstrum v. Centene Corporation, targets investors who purchased Centene securities between December 12, 2024, and June 30, 2025 [1]. - The complaint claims that Centene's leadership provided a misleadingly optimistic view of projected revenue growth, strong enrollment, and low morbidity levels, which contradicted internal data [2]. Group 2: Financial Impact - On July 1, 2025, Centene withdrew its 2025 financial guidance after an independent actuarial review indicated that market growth was "lower than expected" and morbidity levels were "materially inconsistent" with prior assumptions, leading to a stock price drop of over 40% [3]. - Following the lawsuit, Centene reported a Q2 diluted loss per share of -$0.51, attributed to reduced revenue estimates [4]. Group 3: Investigation and Whistleblower Information - Hagens Berman, a national plaintiffs' rights law firm, is investigating claims on behalf of investors who suffered losses, focusing on whether Centene misrepresented its marketplace business health [5]. - The firm encourages whistleblowers with non-public information about Centene to come forward, offering potential rewards of up to 30% of any successful SEC recovery [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3].

CLASS PERIOD: December 12, 2024 to June 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors began to question the veracity of defendants' public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Partic ...